Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications.
In primary hyperparathyroidism, adenoma size is a major determinant of disease severity and manner of presentation, but the reason for the large variation in size (>100-fold) is unknown. One factor could be the level of vitamin D nutrition, because in India, where vitamin D deficiency is endemic, adenomas are larger and the disease more severe than in the U.S. Accordingly, we determined the relationship between vitamin D nutrition, as measured by serum levels of 25-hydroxyvitamin D (25OHD), and parathyroid gland weight, expressed on a logarithmic scale, in 148 U.S. patients with primary hyperparathyroidism. A significant inverse relationship was found between log gland weight as dependent variable and serum 25OHD as independent variable (r = -0.365; P < 0.0001). The only other influence on gland weight was a weak inverse correlation with age. Log gland weight as an independent variable was significantly related to adjusted calcium, PTH, and alkaline phosphatase (AP) as dependent variables. In 51 patients with serum 25OHD levels less than 15 ng/mL, gland weight, PTH, AP, and adjusted calcium were each significantly higher than in 97 patients with 25OHD levels of 15 ng/mL or more, but 1,25-dihydroxyvitamin D levels were similarly increased in both groups. In the former group the response of adjusted calcium to PTH was blunted, and the response of AP was enhanced, based on significant differences in regression slopes (P = 0.0004 and 0.0022, respectively). Suboptimal vitamin D nutrition stimulates parathyroid adenoma growth by a mechanism unrelated to hypocalcemia or 1,25-dihydroxyvitamin D deficiency and reduces the calcemic response to PTH, so that a higher PTH level and more parathyroid cells are needed to raise the patient's serum calcium to the level corresponding to the increased set-point that is characteristic of the disease. Improved vitamin D nutrition in the population is partly, perhaps largely, responsible for the historical changes in disease severity and manner of presentation that have occurred over the last 50 yr.
Rao
D S
DS
Department of Medicine, Henry Ford Health System, Detroit, Michigan 48202, USA. danrao50@hotmail.com
Honasoge
M
M
Divine
G W
GW
Phillips
E R
ER
Lee
M W
MW
Ansari
M R
MR
Talpos
G B
GB
Parfitt
A M
AM
D000236:Adenoma / Q000473:pathology*; D002117:Calcitriol / Q000172:deficiency; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D006961:Hyperparathyroidism / Q000097:blood / Q000209:etiology; D006996:Hypocalcemia / Q000097:blood / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009752:Nutritional Status / Q000502:physiology*; D009929:Organ Size; D010281:Parathyroid Hormone / Q000097:blood / Q000627:therapeutic use; D010282:Parathyroid Neoplasms / Q000473:pathology*; D012189:Retrospective Studies; D014807:Vitamin D / Q000097:blood / Q000502:physiology*
D010281:Parathyroid Hormone; D014807:Vitamin D; D002117:Calcitriol